OLVIG
HOWL icon

Oliver Lagore Vanvalin Investment Group’s Werewolf Therapeutics HOWL Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-580
Closed -$3K – 715
2022
Q3 		$3K Hold
580
– – ﹤0.01% 496
2022
Q2 		$2K Hold
580
– – ﹤0.01% 495
2022
Q1 		$3K Buy
+580
New +$4.06K ﹤0.01% 466

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's HOWL Position: Q4 2022 in Review

Oliver Lagore Vanvalin Investment Group sold out of Werewolf Therapeutics (HOWL) in Q4 2022, closing a stake of 580 shares — an estimated $3K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in HOWL in Q1 2022 and held it in 3 quarters. The position peaked at $3K in Q3 2022. 39 funds tracked by Wall St. Rank hold HOWL as of Q4 2022.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Werewolf Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 580 Werewolf Therapeutics shares in Q4 2022, an estimated $3K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Werewolf Therapeutics in Q1 2022 and held it in 3 quarters.
  • Oliver Lagore Vanvalin Investment Group's Werewolf Therapeutics position peaked at $3K in Q3 2022.
  • 39 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2022.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2022, filed 2 Mar 2023.